 Connection
Rohit Katial to Asthma
This is a "connection" page, showing publications Rohit Katial has written about Asthma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.599 |
|
|
|
-
Katial RK, Wechsler ME, Akuthota P, Jackson DJ, Pavord I, Rogers L, Jackson DJ, Smolen J, Lega Hoyte FC. Consensus summary on the definition of asthma remission. J Allergy Clin Immunol. 2025 Sep; 156(3S):S20-S24.
Score: 0.391
-
Katial RK, Hoyte FCL. Comment on geographic variation in disease burden among patients with severe persistent asthma in the United States. Ann Allergy Asthma Immunol. 2024 05; 132(5):551-552.
Score: 0.356
-
Katial JM, Hoyte FCL, Khatiwada A, Katial RK. Allergen skin test responses in broad U.S. asthma population in those with and without rhinitis. Allergy Asthma Proc. 2024 May 01; 45(3):158-165.
Score: 0.356
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022 08; 39(8):3862-3865.
Score: 0.313
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 05; 39(5):2065-2084.
Score: 0.307
-
Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, Jacobs JS, Kraft M, Martin RJ, Nair P, Wechsler ME. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2S):S1-S14.
Score: 0.215
-
Katial RK. A renewed focus on safety, efficacy, and use of inhaled corticosteroids in asthma. Ann Allergy Asthma Immunol. 2016 12; 117(6):575-576.
Score: 0.213
-
Dunn NM, Katial RK. Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease. Immunol Allergy Clin North Am. 2016 08; 36(3):503-14.
Score: 0.208
-
Katial RK. Severe Asthma: A Heterogeneous Disease. Immunol Allergy Clin North Am. 2016 08; 36(3):xv-xvi.
Score: 0.208
-
Katial RK. Biologics in practice: A unique opportunity for allergist/immunologist expertise. Ann Allergy Asthma Immunol. 2016 Aug; 117(2):105-7.
Score: 0.208
-
Fountain CR, Mudd PA, Ramakrishnan VR, Sillau SH, Kingdom TT, Katial RK. Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2013 Nov; 111(5):337-41.
Score: 0.170
-
Katial RK, Covar RA. Bronchoprovocation testing in asthma. Immunol Allergy Clin North Am. 2012 Aug; 32(3):413-31.
Score: 0.157
-
Katial RK. Update on biomarkers in allergy and asthma. Preface. Immunol Allergy Clin North Am. 2012 Aug; 32(3):ix.
Score: 0.157
-
Katial RK, Bernstein D, Prazma CM, Lincourt WR, Stempel DA. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc. 2011 Mar-Apr; 32(2):127-36.
Score: 0.141
-
Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb; 31(1):68-75.
Score: 0.132
-
Gogate S, Katial R. Pediatric biomarkers in asthma: exhaled nitric oxide, sputum eosinophils and leukotriene E4. Curr Opin Allergy Clin Immunol. 2008 Apr; 8(2):154-7.
Score: 0.117
-
Katial R, Stewart L. Exhaled nitric oxide: a test for diagnosis and control of asthma? Curr Allergy Asthma Rep. 2007 Nov; 7(6):459-63.
Score: 0.113
-
Wang E, Henley W, Larenas-Linnemann D, Bulathsinhala L, Tran TN, Wechsler ME, Aaron SD, Al-Ahmad M, Al-Lehebi R, Altraja A, Barker P, Beastall A, Belevskiy AS, Bergeron C, Bjermer L, Björnsdóttir US, Bosnic-Anticevich SZ, Bourdin A, Brusselle GG, Busby J, Canonica GW, Carter V, Chapman KR, Chapman N, Christoff GC, Cosio BG, Costello RW, Fingleton J, Fonseca JA, Gaga M, Gibson PG, Hansen S, Heaney LG, Heffler E, Hew M, Horiguchi T, Hoyte F, Hubbard RB, Iwanaga T, Jackson DJ, Katial R, Koh MS, Kostikas K, Kuna P, Lehmann S, Lehtimäki L, Louis R, Lúdvíksdóttir D, Lugogo N, Mahboub B, Martin N, Máspero J, Menzies-Gow AN, Mohan A, Murray RB, Nagano T, Papadopoulos NG, Papaioannou AI, Patel PH, Perez-de-Llano L, Perng DW, Peters MJ, Pfeffer PE, Pitrez PM, Pleasants RA, Popov TA, Porsbjerg CM, Puggioni F, Quinton A, Rhee CK, Sadatsafavi M, Salvi S, Scioscia G, Sheu CC, Sirena C, Taillé C, Taube C, Torres-Duque CA, Tsai MJ, Tunsäter A, Ulrik CS, Price DB. Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach. J Allergy Clin Immunol Pract. 2025 Dec; 13(12):3296-3315.
Score: 0.098
-
Smolen J, Sands BE, Jackson DJ, Wechsler ME, Jackson DJ, Akuthota P, Lega Hoyte FC, Pavord I, Katial RK, Rogers L. Asthma remission in the context of other immune-mediated diseases. J Allergy Clin Immunol. 2025 Sep; 156(3S):S1-S6.
Score: 0.098
-
Pavord I, Katial RK, Jackson DJ, Rogers L, Lega Hoyte FC, Smolen J, Wechsler ME, Akuthota P, Jackson DJ. Current data on biologics: Evaluating clinical remission in asthma. J Allergy Clin Immunol. 2025 Sep; 156(3S):S15-S19.
Score: 0.098
-
Jackson DJ, Akuthota P, Lega Hoyte FC, Pavord I, Katial RK, Smolen J, Rogers L, Jackson DJ, Wechsler ME. A critical look at the lexicon, parameters, and limitations of asthma remission definitions. J Allergy Clin Immunol. 2025 Sep; 156(3S):S7-S14.
Score: 0.098
-
Sadatsafavi M, Tran TN, Scelo G, Tsai MJ, Busby J, Emmanuel B, Heaney LG, Jenkins C, Hoyte F, Canonica GW, Katial R, Heffler E, Wang E, Puggioni F, Wechsler ME, Ardusso LRF, Máspero J, Sivori M, Emmas C, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Cochrane B, Denton E, Gibson PG, Hew M, Middleton PG, Peters MJ, Brusselle GG, Louis R, Schleich F, Christoff GC, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Jiménez-Maldonado L, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Altraja A, Bourdin A, Exarchos KP, Gogali A, Kostikas K, Makris MP, Papaioannou AI, Mitchell PD, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Larenas-Linnemann D, Aarli BB, Kuna P, Chaves Loureiro C, Al-Lehebi R, Bulkhi AA, Chen W, Juang YR, Koh MS, Liu A, Rhee CK, Cosio BG, Perez-de-Llano L, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Jackson DJ, Patel PH, Pfeffer PE, Lugogo N, Pleasants RA, Beastall A, Bulathsinhala L, Carter V, Eleangovan N, Fletton K, Townend J, Murray RB, Price DB. Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. Am J Respir Crit Care Med. 2025 Jul; 211(7):1165-1174.
Score: 0.096
-
Chen W, Tran TN, Townend J, Christoff GC, Tsai MJ, Altraja A, Cochrane B, Cosio BG, Sivori M, Murray RB, Makris MP, Scelo G, Bulathsinhala L, Ardusso LRF, Franchi ME, Máspero J, Saldarini F, Stok AM, Tomaszuk AG, Yañez A, Emmanuel B, Emmas C, Kostikas K, Menzies-Gow AN, Stjepanovic N, Bosnic-Anticevich SZ, Denton E, Gibson PG, Hew M, Jenkins C, Middleton PG, Peters MJ, Upham JW, Brusselle GG, Louis R, Schleich F, Pitrez PM, Popov TA, Bergeron C, Bhutani M, Chapman KR, Côté A, Couillard S, Dorscheid DR, Lougheed MD, Sadatsafavi M, Celis-Preciado CA, Jiménez-Maldonado L, Rodríguez-Cáceres B, Cano Rosales DJ, Solarte I, Torres-Duque CA, Hansen S, Porsbjerg CM, Ulrik CS, Bourdin A, Bakakos P, Exarchos KP, Gogali A, Ladias AA, Papadopoulos NG, Papaioannou AI, Costello RW, Cushen B, Mitchell PD, Canonica GW, Heffler E, Puggioni F, Iwanaga T, Nagano T, Tohda Y, Al-Ahmad MS, Larenas-Linnemann D, Aarli BB, Lehmann S, Kuna P, Ferreira JA, Fonseca JA, Loureiro CC, Al-Lehebi R, Bulkhi AA, Juang YR, Koh MS, Liu A, Rhee CK, Perez-de-Llano L, Fu PK, Perng DW, Sheu CC, Wang HC, Mahboub B, Salameh L, Busby J, Heaney LG, Jackson DJ, Patel PH, Pfeffer PE, Hoyte F, Katial RK, Lugogo N, Pleasants RA, Wang E, Wechsler ME, Beastall A, Carter V, Eleangovan N, Fletton K, Price DB. Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data. J Allergy Clin Immunol Pract. 2025 Aug; 13(8):2033-2048.
Score: 0.095
-
Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024 Oct 01; 210(7):869-880.
Score: 0.092
-
Gauvreau GM, Sehmi R, FitzGerald JM, Leigh R, Cockcroft DW, Davis BE, Mayers I, Boulet LP, Al-Sajee D, Salter BM, Cusack RP, Ho T, Whetstone CE, Alsaji N, Satia I, Killian KJ, Mitchell PD, Magee IP, Bergeron C, Bhutani M, Werkström V, Durzynski T, Shoemaker K, Katial RK, Jison M, Newbold P, McCrae C, O'Byrne PM. Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial. Eur Respir J. 2024 Sep; 64(3).
Score: 0.091
-
Rivera O, Katial R, Hoyte FCL. Biologics in Asthma: Potential to Achieve Clinical Remission. Immunol Allergy Clin North Am. 2024 11; 44(4):725-736.
Score: 0.091
-
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. Eur Respir J. 2024 Jul; 64(1).
Score: 0.090
-
Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2347-2361.
Score: 0.089
-
Li X, Newbold P, Katial R, Hirsch I, Li H, Martin UJ, Meyers DA, Bleecker ER. Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness. J Allergy Clin Immunol Pract. 2024 Oct; 12(10):2732-2743.
Score: 0.089
-
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Lawkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024; 15:1361891.
Score: 0.089
-
Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, Murray RB, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, García U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, Perez de Llano L, Perng DS, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Goddard AG, Wang E, Hoyte FCL, Chapman NM, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Porsbjerg C, Price DB. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2024 02 01; 209(3):262-272.
Score: 0.087
-
Xu X, Schaefer C, Szende A, Genofre E, Katial R, Chung Y. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective. J Manag Care Spec Pharm. 2023 Nov; 29(11):1193-1204.
Score: 0.086
-
Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, Linnemann DL, Garcia U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, de Llano LP, Perng Steve DW, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson D, Busby J, Heaney LG, Pfeffer P, Goddard AG, Wang E, Hoyte F, Wechsler ME, Chapman N, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Price DB, Porsbjerg C. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024 01; 132(1):42-53.
Score: 0.085
-
Katial RK. Cockroach allergy. Immunol Allergy Clin North Am. 2003 Aug; 23(3):483-99.
Score: 0.084
-
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, Hirsch I, Katial R, Li X. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. J Allergy Clin Immunol Pract. 2023 06; 11(6):1805-1813.
Score: 0.082
-
Peters AT, Bengtson LGS, Chung Y, Emmanuel B, Katial RK, Kreindler JL, Blauer-Peterson CJ, Davis GE. Clinical and economic burden of chronic rhinosinusitis with nasal polyposis: A U.S. administrative claims analysis. Allergy Asthma Proc. 2022 09 01; 43(5):435-445.
Score: 0.079
-
Davis GE, Zeiger RS, Emmanuel B, Chung Y, Tran TN, Evans KA, Chen S, Katial R, Kreindler JL, Tkacz J. Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis. Clin Ther. 2022 09; 44(9):1187-1202.
Score: 0.079
-
Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022 06; 128(6):669-676.e6.
Score: 0.077
-
Brown LL, Patterson HS, Katial RK. A case of cyclical asthma exacerbations and associated left upper lobe collapse. Ann Allergy Asthma Immunol. 2002 Jan; 88(1):18-23.
Score: 0.076
-
Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. J Allergy Clin Immunol Pract. 2020 02; 8(2):540-548.e1.
Score: 0.064
-
Comberiati P, Katial RK, Covar RA. Bronchoprovocation Testing in Asthma: An Update. Immunol Allergy Clin North Am. 2018 11; 38(4):545-571.
Score: 0.061
-
Hoyte FCL, Katial RK. Biomarkers in Allergy and Asthma. Immunol Allergy Clin North Am. 2018 11; 38(4):xiii-xiv.
Score: 0.061
-
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 02; 7(2):589-596.e3.
Score: 0.060
-
Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ. A drug interaction between zafirlukast and theophylline. Arch Intern Med. 1998 Aug 10-24; 158(15):1713-5.
Score: 0.060
-
Prazma CM, Katial R, Howarth P, Bradford E, Martin N, Pizzichini E. Rigor Is Needed When Making Comparative Analyses of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2018 06 01; 197(11):1508-1510.
Score: 0.059
-
Que LG, Yang Z, Lugogo NL, Katial RK, Shoemaker SA, Troha JM, Rodman DM, Tighe RM, Kraft M. Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. Immun Inflamm Dis. 2018 06; 6(2):322-331.
Score: 0.058
-
Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 07; 142(1):171-177.e1.
Score: 0.058
-
Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA, Peters SP, Farrar JR. Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017 02; 118(2):133-142.e3.
Score: 0.054
-
Katial RK, Martucci M, Burnett T, Faino A, Finkas L, Liu S, Alam R. Nonsteroidal anti-inflammatory-induced inhibition of signal transducer and activator of transcription 6 (STAT-6) phosphorylation in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016 08; 138(2):579-85.
Score: 0.050
-
Chen Z, Wang S, Erekosima N, Li Y, Hong J, Qi X, Merkel P, Nagabhushanam V, Choo E, Katial R, Alam R, Trikha A, Chu HW, Zhuang Y, Jin M, Bai C, Huang H. IL-4 confers resistance to IL-27-mediated suppression on CD4+ T cells by impairing signal transducer and activator of transcription 1 signaling. J Allergy Clin Immunol. 2013 Oct; 132(4):912-21.e1-5.
Score: 0.042
-
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov; 132(5):1086-1096.e5.
Score: 0.042
-
Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010 Oct; 126(4):738-44.
Score: 0.034
-
Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010 Jun; 125(6):1237-1244.e2.
Score: 0.034
-
Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, McFadden ER, Pixton GC, Barrett RJ. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imaging. 2009 Nov; 2(6):492-8.
Score: 0.032
-
Hicks M, Brugman SM, Katial R. Vocal cord dysfunction/paradoxical vocal fold motion. Prim Care. 2008 Mar; 35(1):81-103, vii.
Score: 0.029
-
Stewart L, Katial R. Exhaled nitric oxide. Immunol Allergy Clin North Am. 2007 Nov; 27(4):571-86; v.
Score: 0.028
-
Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, Wenzel SE. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol. 2005 Dec; 116(6):1249-55.
Score: 0.025
-
Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol. 2004 Nov; 114(5):1241-56.
Score: 0.023
-
Gitomer SA, Fountain CR, Kingdom TT, Getz AE, Sillau SH, Katial RK, Ramakrishnan VR. Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis. Otolaryngol Head Neck Surg. 2016 07; 155(1):173-8.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|